Pregabalin (DrugBank: Pregabalin)
5 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 3 |
| 36 | 表皮水疱症 | 1 |
| 46 | 悪性関節リウマチ | 1 |
| 70 | 広範脊柱管狭窄症 | 6 |
| 298 | 遺伝性膵炎 | 4 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-101335 | 01/9/2010 | 08/11/2010 | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain) | Spinal Cord Diseases, Spinal Cord Injuries, Neuralgia, Pain | Intervention name : pregabalin INN of the intervention : pregabalin Dosage And administration of the intervention : pregabalin capsules 150mg/day, 300mg/day, 450mg/day or 600mg/day BID Control intervention name : null | Pfizer Japan Inc. | NULL | 18 | BOTH | 100 | Phase 3 | NULL | ||
| 2 | NCT01202227 (ClinicalTrials.gov) | September 2010 | 31/8/2010 | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain | An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain) | Spinal Cord Diseases;Spinal Cord Injuries;Neuralgia;Pain | Drug: pregabalin | Pfizer | NULL | Completed | 18 Years | N/A | All | 104 | Phase 3 | Japan |
| 3 | NCT00291148 (ClinicalTrials.gov) | March 2006 | 10/2/2006 | Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain | A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine | Neuropathic Pain;Multiple Sclerosis | Drug: paroxetine;Drug: pregabalin;Drug: Paroxetine | University of Manitoba | NULL | Completed | 18 Years | 65 Years | Both | 75 | Phase 3 | Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03928093 (ClinicalTrials.gov) | August 7, 2019 | 27/3/2019 | Pregabalin Treatment for RDEB Pain and Itch | A Double-blind, Randomized, Cross-over, Feasibility Trial of Pregabalin for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-associated Neuropathic Pain and Itch | Pain, Neuropathic;Itch;Epidermolysis Bullosa | Drug: Pregabalin | The Hospital for Sick Children | Epidemolysis Bullosa Research Partnership | Recruiting | 8 Years | 40 Years | All | 15 | Phase 3 | Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs041180071 | 13/10/2016 | 07/03/2019 | T-ReX study | Tocilizumab treatment with Reducing and stopping methotreXate in patients with rheumatoid arthritis in stable low disease activity-state - T-ReX study | Rheumatoid arthritis | At week 0, the dosing frequency of MTX was decreased from weekly to biweekly without a change in dose, regardless of the initial dose. At week 12, MTX was discontinued if low disease activity was maintained. TCZ and csDMARDs other than MTX were continued at a stable dose and interval throughout the course of the study. Glucocorticoids were continued at a stable dose up to week 36, and allowed to taper after week 36. The use of oral analgesics (non-steroidal anti-inflammatory drugs, acetaminophen, pregabalin, and tramadol) was not prohibited during the study period. One or more of the following rescue treatments were performed if the CDAI score was >10 and at the discretion of the investigator and/or upon patient request: changing the dosing frequency back to weekly administration, restarting, or increasing doses of MTX; increasing doses of or adding csDMARDs other than MTX or glucocorticoids; and administering an intraarticular injection of corticosteroids, hyaluronic acid, or lidocaine. | Kojima Toshihisa | NULL | Complete | >= 20age old | Not applicable | Both | 51 | N/A | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000028775 | 2020-02-01 | 2020-01-03 | Safety and effectiveness of pregabalin in the management of postoperative pain in lumbar surgery | Safety and effectiveness of pregabalin in the management of postoperative pain in lumbar surgery | 1. Lumbar disc herniation; 2. Lumbar spinal stenosis; 3. Lumbar spondylolisthesis | Pregabalin group: ?????????? ?????????? Postoperative analgesia with pregabalin;Celecoxib group: Postoperative analgesia with celecoxib; | The First Affiliated Hospital of Chongqing Medical University | NULL | Recruiting | 18 | 80 | Both | Pregabalin group:60;Celecoxib group:60; | China | |
| 2 | NCT03584074 (ClinicalTrials.gov) | July 1, 2018 | 29/6/2018 | Clinical Trial of Pregabalin and COX2 in Spinal Stenosis | Comparative Study for Decrease of Pain Intensity and Pain Sensitivity Between Pregabalin + COX-2 Inhibitor and COX-2 Inhibitor in Patients With Lumbar Spinal Stenosis: Randomized Controlled Trial | Spinal Stenosis Lumbar | Drug: Pregabalin 75mg;Drug: Celebrex 200Mg Capsule | Seoul National University Bundang Hospital | NULL | Unknown status | 40 Years | N/A | All | 60 | Phase 4 | NULL |
| 3 | NCT01888536 (ClinicalTrials.gov) | February 2013 | 25/6/2013 | A Study to Evaluate Efficacy of ?Opast Tablet?for Neurologic Claudication in Patients With Lumbar Spinal Stenosis | A Randomized, Double-Blind, Comparative, Multi-Center, Phase ? Clinical Trial to Evaluate Efficacy of ?Opast Tablet?for Neurologic Claudication in Patients With Lumbar Spinal Stenosis | Neurologic Claudication in Patients With Lumbar Spinal Stenosis | Drug: Limaprost;Drug: Pregabalin;Drug: Placebo(for Pregabalin);Drug: Placebo(for Limaprost) | Yungjin Pharm. Co., Ltd. | NULL | Completed | 20 Years | 75 Years | Both | 182 | Phase 4 | Korea, Republic of |
| 4 | JPRN-UMIN000007419 | 2012/04/01 | 01/04/2012 | A Prospective, Randomized, Multicenter Trial of Pregabalin and Celecoxib for Lumbar Spinal Stenosis | Lumbar Spinal Stenosis | Celecoxib Pregabalin | Department of Orthopedic Surgery Kobe University Graduate School of Medicine | NULL | Pending | 50years-old | 90years-old | Male and Female | 80 | Not selected | Japan | |
| 5 | NCT00908375 (ClinicalTrials.gov) | May 2009 | 21/5/2009 | Efficacy of Pregabalin in Patients With Radicular Pain | Efficacy of Pregabalin in Patients With Radicular Pain | Neuropathy; Radicular, Lumbar, Lumbosacral;Failed Back Surgery Syndrome;Spinal Stenosis;Herniated Disc | Drug: Pregabalin;Drug: Sugar Pill | Northwestern University | NULL | Completed | 18 Years | 64 Years | All | 39 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00638443 (ClinicalTrials.gov) | March 2008 | 12/3/2008 | Lumbar Stenosis Outcomes Research (LUSTOR) | Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Cross-over Trial of Pregabalin vs. Diphenhydramine in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain | Lumbar Spinal Stenosis | Drug: Pregabalin;Drug: Diphenhydramine | University of Rochester | Pfizer | Completed | 50 Years | N/A | All | 29 | Phase 4 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01528540 (ClinicalTrials.gov) | April 2012 | 27/1/2012 | Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a Randomized Control Trial | Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a RCT | Chronic Pancreatitis | Drug: Placebo;Drug: Antioxidant plus Pregabalin | Asian Institute of Gastroenterology, India | NULL | Completed | 18 Years | 65 Years | Both | 87 | N/A | India |
| 2 | EUCTR2009-010266-28-NL (EUCTR) | 21/07/2009 | 29/01/2009 | Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitis | Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitis | chronische pancreatitis MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis | Trade Name: Lyrica® | Afdeling heelkunde, Universitair Medisch Centrum Sint Radboud | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Netherlands | |||
| 3 | NCT00755573 (ClinicalTrials.gov) | October 2008 | 18/9/2008 | Pain and Chronic Pancreatitis - Clinical End Experimental Studies | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic Pancreatitis | Chronic Pancreatitis | Drug: Pregabalin;Drug: placebo | Aalborg Universitetshospital | Radboud University | Completed | 18 Years | 75 Years | Both | 64 | Phase 2;Phase 3 | Denmark;Netherlands |
| 4 | EUCTR2008-002671-27-DK (EUCTR) | 14/07/2008 | 30/05/2008 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITIS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITIS | Chronic pancreatitis MedDRA version: 9.1;Level: LLT;Classification code 10033649;Term: Pancreatitis chronic | Trade Name: Lyrica INN or Proposed INN: pregabalin INN or Proposed INN: Pregabalin | Department of Medical Gastroenterology | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 3 | Denmark |